Blocking a fertility hormone to fight cancer
2815 Eastlake Avenue East
Welcome to Scrip
Create an account to read this article
Already a subscriber?
CG Therapeutics Inc.
It sometimes happens that a medicine developed for one purpose is discovered to work wonderfully well in other, initially unanticipated indications. The founders of CG Therapeutics believe they can benefit from just such serendipity. The start-up company is developing a molecule first pursued at Ohio State University as a long-acting contraceptive some 30 years ago, now as a cancer vaccine meant to treat solid tumors.
More from Strategy
• By
Also deals involving Xspray/Handa, Fosun/Expedition, Kaken/Astria, Orchid/Allecra, Sanofi/Visirna, KKR/Healthcare Royalty Partners, Viridian/Kissei, Sandoz/Evotec, Dx&Vx, Dr. Falk/Allianthera, Madrigal/CSPC and Lilly/LTZ.
• By
Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.
• By
The French drugmaker's anti-CD38 antibody has racked up another approval in first-line multiple myeloma, but it marks a small victory while the company develops a subcutaneous version to help level the field with J&J’s Darzalex.
• By
Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.
More from Business
• By
Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.
• By
Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.
• By
Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.